Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Collaborations Pharmaceuticals Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's current patent activities cover different technical sub-specialties or applications within the pharmaceutical field.
The busiest examiner for this portfolio is RICCI, CRAIG D, who is responsible for 1 pending office action. This represents half of the current pending workload for the organization. Because the 2 pending office actions are in 2 distinct art units, the applicant must navigate different administrative environments and potentially different examination standards for each case.
The presence of 2 distinct examiners across 2 distinct art units for only 2 pending office actions suggests a lack of concentration in the prosecution pipeline. Practitioners must be prepared to adapt their strategies to the specific requirements of RICCI, CRAIG D and the other involved examiner. Efficiently managing these 2 pending office actions requires careful coordination to ensure that the technical disclosures remain consistent across the different art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720768 | VANDETANIB REDUCES INFLAMMATORY CYTOKINES AND AMELIORATES COVID-19 | RICCI, CRAIG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18220034 | USE OF PYRONARIDINE, TILORONE, AND QUINACRINE AGAINST MARBURG VIRUS AND OTHER VIRUS INFECTIONS | HERNANDEZ, JACKSON J | 56d |
| 18720768 | VANDETANIB REDUCES INFLAMMATORY CYTOKINES AND AMELIORATES COVID-19 | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720768 | VANDETANIB REDUCES INFLAMMATORY CYTOKINES AND AMELIORATES COVID-19 | RICCI, CRAIG D | 1611 | §102§103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18220034 | USE OF PYRONARIDINE, TILORONE, AND QUINACRINE AGAINST MARBURG VIRUS AND OTHER VIRUS INFECTIONS | HERNANDEZ, JACKSON J | 1627 | §103 | Non-Final OA | 56d | Pending | Jul 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCollaborations Pharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Craig D Ricci has the most, with 1 of Collaborations Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
